AbbVie announces European Commission approval of AQUIPTA® (atogepant) for the preventive treatment of migraine in adults

AbbVie (NYSE: ABBV) announced that the European Commission has approved AQUIPTA® (atogepant) for the prophylaxis of migraine in adults who have four or more migraine days per month. The approval makes AQUIPTA the first and only once-daily oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) treatment in the European Union for the preventive treatment of both chronic and episodic migraine.

from Breaking World Pharma News https://ift.tt/3EyTCpR